Researchers from Smith & Nephew (NYSE:SNN;LSE:SN), the global medical technology business, presented their abstract titled, “Factors that Influence Taper Corrosion: Learning from an 18-year Retrieval Database” at the 11th Congress of the European Hip Society (EHS) in Stockholm, Sweden. Named as one of the meeting’s best abstracts by the Society’s scientific committee, the abstract looked at femoral head retrievals to identify potential factors that relate to the incidence and severity of taper corrosion in hip replacements.
The findings of the study revealed that neither head size nor time spent in vivo significantly correlated with higher taper corrosion scores. However, both head material and offset did, with OXINIUM◊ heads showing no measurable material loss due to corrosion at the taper.
“We’re very honoured that our abstract was named as one of the best by the European Hip Society,” said Laura Whitsitt, Divisional Senior Vice President of Research and Emerging Technologies at Smith & Nephew.
“Cobalt chrome heads have a 20-plus year track record of clinical success. However, as a company committed to bringing innovative solutions to the market and improving healthcare for patients and providers, we’re pleased to have data showing that OXINIUM femoral heads may offer a significant clinical benefit compared to cobalt chrome when it comes to reducing taper corrosion at the head-stem junction.”
The abstract will also be published in a forthcoming issue of “Hip International.”
Facts about the study
The issue of taper corrosion typically refers to a reaction that occurs at the junction between the femoral head, or ball portion of the implant, and the hip stem taper. Because these two implant components can be made of different materials, micro-movements and electrochemical reactions can cause corrosion to occur at the contacting surfaces. This type of corrosion, termed as mechanically assisted crevice corrosion (MACC), can lead to an adverse local tissue response (ALTR) which may require revision of the original hip replacement.1
For their study, Smith & Nephew researchers looked at 204 femoral heads that had been revised between 1997 and 2014. All of the femoral heads studied were made of either cobalt-chromium-molybdenum (CoCrMo), the most commonly used material for femoral heads, or oxidized zirconium (OxZr), a Smith & Nephew proprietary material marketed under the brand name OXINIUM. In addition to head material, the researchers also compared the effect of head size, femoral neck offset and the amount of time spent in vivo on the taper corrosion scores.
About OXINIUM™ Oxidized Zirconium:
OXINIUM implants are made from a biocompatible and corrosion resistant zirconium and niobium alloy that is heated to produce a ceramicized outer surface. Because of this ceramic surface, OXINIUM femoral heads offer the benefit of ceramics heads without the fracture risk.2
Editor’s Note:
There are multiple factors that may contribute to taper corrosion. While this study looked at several factors, additional factors such as impaction force, taper cleanliness, stem materials, patient-to-patient variability and stem designs were not studied.
Contacts:
| Media |
|
| Joe Metzger Smith & Nephew
|
|
| Investor/Analyst |
|
| Ingeborg Oie Smith & Nephew | +44 (0)20 7401 7646 |
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 90 countries. Annual sales in 2013 were more than $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
◊ Trademark of Smith & Nephew. Registered US Patent and Trademark Office.
References
1Jacobs JJ, Cooper HJ, Urban RM, Wixson RL, Della Valle CJ, “What do we know about taper corrosion in total hip arthroplasty,” J Arthroplasty. 2014 Apr;29 (4):6689. http://www.ncbi.nlm.nih.gov/pubmed/24655613
2G. Hadley Callaway, MD, William Flynn, MD, Chitranjan S. Ranawat, MD,and Thomas R Sculco, MD. Fracture of the Femoral Head After Ceramic-on-polyethylene Total Hip Arthroplasty. Journal of Arthroplasty; Vol. 10 No. 6: 1995.